Nanomedical Diagnostics Changes Name to Cardea

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced that it has changed its name to Cardea, to encompass internet biology of things.

Michael Heltzen, the new Co-CEO of Cardea says, “The name Cardea - the Roman goddess of hinges and therefore gates - underlines the pivotal and unique aspect of our proprietary graphene biosensor platform. We allow the biological molecules of interest to be the critical part of the electrical system that makes up our biosensors. This way we connect biology to the digital networks in a way the world has never seen before. This direct integration of biology and computing power gives us a live signal from the complex actions and interactions of the biology we normally think of as disease, health, drugs, food and more.”

Cardea is the world’s leading manufacturer and developer of breakthrough digital graphene biosensors that among other things are being used to power the Internet of Biology. Cardea’s mission is to help transform the life science and healthcare industries with innovative new capabilities that enable Cardea partners to offer the world next-generation pharmaceutical development and monitoring, rapid onsite diagnostics, and cutting-edge life science applications.

Source: https://www.prweb.com/releases/nanomedical_diagnostics_announces_company_name_change_to_cardea_to_encompass_internet_of_biology_initiatives/prweb16034251.htm

Spatial Powers First Social Media Segmentation For Real Estate

Spatial, a Serra Capital III portfolio company, has announced the launch of its newest GeoSocial dataset that organizes billions of social media content into actionable segments that reveals the characteristics of communities down to the very block group.

Spatial.ai is the world's first human-driven location dataset - built by categorizing billions of conversations from social networks into actionable consumer segments. Companies like Ford, SiteZeus, Payless, and Intalytics, all use GeoSocial data to predict demand, select locations and uncover the human-driven data that has a bottom line impact on their business.


Metactive Medical Among "12 Kansas City Startups to Watch in 2019"

Metactive Medical, a Serra Capital III portfolio company, was recently featured by Startland as one of “12 Kansas City Startups to Watch in 2019.” Metactive was chosen as a top 12 company from a pool of 250 companies, and was judged on leadership, disruptiveness, traction and the likelihood of major news in 2019.

Metactive is developing novel, endovascular medical devices for the treatment of peripheral and neurovascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform.

Source: https://www.startlandnews.com/2019/01/kansas-city-startups-to-watch/